Cargando…
Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma
BACKGROUND: Sagopilone is a novel fully synthetic epothilone with promising preclinical activity and a favourable toxicity profile in phase I testing. METHODS: A phase II pharmacokinetic and efficacy trial was conducted in patients with metastatic melanoma. Patients had measurable disease, Eastern C...
Autores principales: | DeConti, R C, Algazi, A P, Andrews, S, Urbas, P, Born, O, Stoeckigt, D, Floren, L, Hwang, J, Weber, J, Sondak, V K, Daud, A I |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990578/ https://www.ncbi.nlm.nih.gov/pubmed/20924376 http://dx.doi.org/10.1038/sj.bjc.6605931 |
Ejemplares similares
-
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012) -
Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
por: Daud, A. I., et al.
Publicado: (2010) -
Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial
por: Arnold, D, et al.
Publicado: (2009) -
A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma
por: Ott, Patrick A., et al.
Publicado: (2010) -
Molecular Mode of Action and Role of TP53 in the Sensitivity to the
Novel Epothilone Sagopilone (ZK-EPO) in A549 Non-Small Cell Lung Cancer
Cells
por: Winsel, Sebastian, et al.
Publicado: (2011)